

Leaps by Bayer

Breaking Through Impossible

Capital Markets Day March 10-11, 2021

Jürgen Eckhardt

Head of Leaps by Bayer

leaps S RAYER





Cautionary Statements Regarding Forward-Looking Information

This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management.

Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at http://www.bayer.com/.

The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.



Leaps is The Strategic Impact Investment Unit of Bayer

Breaking through impossible

APPROACH

- // Leaps' mission: Invest in breakthrough technologies and disruptive business models
- // Use minority equity to found new and invest into existing start-ups
- Focus on early-stage innovation in the life sciences (across all divisions)
- // Create business models balancing financial return with sustainability
- // Advancing from treatment to cure/ prevention in health and from more to better in agriculture
- "10 leaps" represent the articulation of the Leaps by Bayer vision and goals

FACTS & FIGURES

- # Established in 2015
- // Invested >1 bn USD, plan to continue investing at similar pace and volume in early 20s
- // Portfolio includes >35 companies
- Well recognized brand in the venture capital space





Health for All – Cure and Prevent Chronic Diseases with Breakthrough Medicines

Strategic Rationale & 10 Leaps: Health

TEN LEAPS

KEY CONSIDERATIONS

Cure genetic diseases

Sustainable organ replacement 2

Reduce environmental impact of agriculture

Prevent and cure cancer 4

Regenerate lost tissue function 5

Reverse autoimmune diseases 6

Cure through microbiome health

Sustainable protein supply

Eradicate insect-borne infections

Transformational digital business models

18th to 20th century

21st century

Mostly symptomatic therapy treatment

Prevention and cure



Leaps investments have driven progress in **next-generation** technologies, e.g.:

- **Regenerative medicine** which offers potential to cure patients that currently can only be treated symptomatically
- Technological progress in one of the most devastating diagnoses: cancer
- Sustainable organ supply









Hunger for None – Create a Sustainable and Nutritious Food Supply by Developing Disruptive Technologies in Agriculture

Strategic Rationale & 10 Leaps: Agriculture

TEN LEAPS	KEY CONSIDERATIONS
-----------	--------------------

Cure genetic diseases

1960s - 2000s:

21st century

Sustainable organ replacement

More food to feed

Reduce environmental impact of agriculture

growing population

leaps

Sustainable agriculture / better food

Prevent and cure cancer

Regenerate lost tissue function

Reverse autoimmune diseases

Cure through microbiome

Sustainable protein supply 8

Eradicate insect-borne infections

Transformational digital business models

Leaps investments have driven progress in **next-generation** technologies to:

- Produce **better food** with **better nutrition**
- Better use of land and resources
- All with much less impact on the environment (climate change, deforestation, pollution, and general environmental degradation)










Leaps by Bayer has Invested in a Diverse Technology Portfolio of Promising Start-up Companies in Health and Agriculture

Portfolio overview





Leaps' Mission is To Invest in New and Potentially Disruptive Technologies - Complementary to Divisional Activities


Role within Bayer innovation landscape

FUNDAMENTAL BREAKTHROUGH APPROACH

CH

ROLE WITHIN BAYER INNOVATION PORTFOLIO

TECHNOLOGICAL RISK



- // Provides access to early-stage potential breakthrough technology platforms
- // Complements internal R&D activities
- // **Directly** reports into the CEO
- // **Dedicated budget** with high freedom to operate





Leaps by Bayer Portfolio Company Example Health: eGenesis

Striving to create a world with no shortage of human transplantable organs



Vision

eGenesis has shown genome-wide inactivation of porcine endogenous retroviruses (PERVs) and **produced the first immunoplex-engineered pig**.

Technology

eGenesis is a **gene editing** and genome engineering company committed to the development **of safe and effective human transplantable organs**, **tissues and cells** to address the global organ crisis.

eGenesis has a **lead program in kidney** and earlier programs in islet cell, liver, heart and lung

Impact

Organ transplantation is currently failing to meet critical patient needs due to a massive gap between organ demand and supply globally. In the U.S alone, more than **118,000 people are in need of an organ**.

Multiple genetic factors make it even more difficult to match an organ donor with a patient. Achieving an **on-demand organ supply** would usher in a new era in medicine, where organ replacement surgery could be scheduled as easily as a hip or knee replacement.





Leaps by Bayer Portfolio Company Example Agriculture: Joyn Bio

Engineering bacteria that live in soil to nurture healthy and sustainable agriculture





Engineer naturally occurring soil microbes and their genes to perform at unprecedented levels with focus on Biofertility (N fixation for corn/cereals) and Crop protection

Technology

Engineered microbe that **enables plants to convert nitrogen from the air** into a form that cereal crops can use, significantly **reducing the amount of traditional chemical fertilizer** currently required.

Joyn is taking this application and **extending it into a flexible ag platform to engineer host microbes** with specific qualities to develop an optimized microbe – this approach will allow Joyn to seamlessly pursue applications in **pest and disease targets**.

Impact

Nitrogen fixation: Reduce the current 3% of worldwide global greenhouse gas emissions coming from industrial nitrogen fertilizers by enabling plants to obtain nitrogen from bacteria that live in the soil.





Find Us At Capital Markets Day 2021

Learn more about Leaps by Bayer and our portfolio companies.

Join the virtual exhibition.



Click the *Leaps* link on the CMD lobby page.



"There are many things that seem impossible.
Only so long as one does not attempt them."

André Gide
French Writer & Nobel Price Winner



Thank you!

Bye-Bye

